Warning: The NCBI web site requires JavaScript to function. more...
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents.
Tan J, Cang S, Ma Y, Petrillo RL, Liu D.
J Hematol Oncol. 2010 Feb 4;3:5. Review.
Related citations
Histone deacetylase inhibitors in the treatment of lymphoma.
Lemoine M, Younes A.
Discov Med. 2010 Nov;10(54):462-70. Review.
Biomarkers for predicting clinical responses to HDAC inhibitors.
Stimson L, La Thangue NB.
Cancer Lett. 2009 Aug 8;280(2):177-83. Epub 2009 Apr 10. Review.
HDAC inhibitors: clinical update and mechanism-based potential.
Glaser KB.
Biochem Pharmacol. 2007 Sep 1;74(5):659-71. Epub 2007 Apr 7.
Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer.
Thurn KT, Thomas S, Moore A, Munster PN.
Future Oncol. 2011 Feb;7(2):263-83. Review.
Histone deacetylase inhibitors: current status and overview of recent clinical trials.
Ma X, Ezzeldin HH, Diasio RB.
Drugs. 2009 Oct 1;69(14):1911-34. doi: 10.2165/11315680-000000000-00000. Review.
Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer.
Martínez-Iglesias O, Ruiz-Llorente L, Sánchez-Martínez R, García L, Zambrano A, Aranda A.
Clin Transl Oncol. 2008 Jul;10(7):395-8. Review.
Histone deacetylase inhibitors in cancer therapy.
Lane AA, Chabner BA.
J Clin Oncol. 2009 Nov 10;27(32):5459-68. Epub 2009 Oct 13. Review.
Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
Santini V, Gozzini A, Ferrari G.
Curr Drug Metab. 2007 May;8(4):383-93. Review.
HDAC inhibitors in cancer care.
Shabason JE, Tofilon PJ, Camphausen K.
Oncology (Williston Park). 2010 Feb;24(2):180-5.
Histone deacetylases and epigenetic therapies of hematological malignancies.
Mercurio C, Minucci S, Pelicci PG.
Pharmacol Res. 2010 Jul;62(1):18-34. Epub 2010 Feb 26. Review.
[Development of HDAC inhibitors].
Sowa Y.
Gan To Kagaku Ryoho. 2010 Sep;37(9):1665-8. Japanese.
Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma.
Kavanaugh SM, White LA, Kolesar JM.
Am J Health Syst Pharm. 2010 May 15;67(10):793-7. Review. Erratum in: Am J Health Syst Pharm. 2010 Jul 15;67(14):1136. Kavanaugh, Shannon A [corrected to Kavanaugh, Shannon M].
Vorinostat in cutaneous T-cell lymphoma.
Duvic M, Vu J.
Drugs Today (Barc). 2007 Sep;43(9):585-99. Review.
Histone deacetylase inhibitors: biology and mechanism of action.
Mehnert JM, Kelly WK.
Cancer J. 2007 Jan-Feb;13(1):23-9. Review.
Histone deacetylase inhibitors from microorganisms: the Astellas experience.
Masuoka Y, Shindoh N, Inamura N.
Prog Drug Res. 2008;66:335, 337-59. Review.
The biology of HDAC in cancer: the nuclear and epigenetic components.
Hagelkruys A, Sawicka A, Rennmayr M, Seiser C.
Handb Exp Pharmacol. 2011;206:13-37. Review.
DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD.
BMC Med Genomics. 2009 Nov 30;2:67.
The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.
Hymes KB.
Clin Lymphoma Myeloma Leuk. 2010 Apr 1;10(2):98-109. Review.
Developing histone deacetylase inhibitors as anti-cancer therapeutics.
Venugopal B, Evans TR.
Curr Med Chem. 2011;18(11):1658-71. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on